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Abstract. Donald (Don) Arthur Berry, born May 26, 1940 in South-
bridge, Massachusetts, earned his A.B. degree in mathematics from
Dartmouth College and his M.A. and Ph.D. in statistics from Yale Uni-
versity. He served first on the faculty at the University of Minnesota
and subsequently held endowed chair positions at Duke University and
The University of Texas M.D. Anderson Center. At the time of the
interview he served as Head of the Division of Quantitative Sciences,
and Chairman and Professor of the Department of Biostatistics at UT
M.D. Anderson Center.
Don’s research deals with the theory and applications of statistics,
especially Bayesian methods for sequential design of experiments. His
work challenges the status quo, always striving to improve design and
analysis of clinical trials, genetic modeling and the process of health-
related decision making. His research impacts health research broadly,
but has achieved the greatest influence in cancer research. As of 2010,
he has published over 200 articles and 10 books and has mentored 24
Ph.D. and 16 M.S. students.
Don’s honors include fellowship election to the International Statisti-
cal Institute, the American Statistical Association and the Institute of
Mathematical Statistics. He gave Presidential invited addresses to the
Western North American Region of the International Biometric Society
(New Mexico, 2004), the Canadian Statistical Society (Ottawa, 2006)
and the Eastern North American Region of the International Biometric
Society (Washington, 2008).
Don married Donna Berry in 1960. Together they raised six children,
Don, Mike, Tim, Scott, Jennifer and Erin. Celebrating Don’s 70th birth-
day, the authors co-organized two invited sessions and a dinner recep-
tion at the ENAR 2010 in New Orleans. This interview occurred while
his family, friends, colleagues and students gathered to celebrate his
birthday and his contributions to statistics.
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Fig. 1. Don in the driveway on the farm, on the way to
meet the school bus. Don always brought his lunch rather than
eating in the cafeteria.
DS: We would like to begin with some questions
that help us put your life in historical context. Where
were you born, how did your parents earn a living,
and what are your earliest recollections of life in the
1940s?
Berry: Oh my! I was born in Southbridge, Massa-
chusetts, in my maternal grandparents’ home, on the
day FDR responded to and tried to comfort Ameri-
cans about Hitler’s invasion of Western Europe in
one of his Fireside Chats. My parents lived in Stur-
bridge. They had a small family farm, 100 acres. My
father was from Beverly, Massachusetts, a suburb of
Boston. He bought the farm before he married. He
paid $3000. It’s pretty nice real estate for $3000,
$25/month for 10 years, no interest. At the time he
worked in the “mill.” Even though most textile mills
had left the Northern U.S. to be closer to the cot-
ton fields of the South, there was still one in South-
bridge. When I was young my mother “didn’t work,”
but in fact she worked her fingers to the bone, “keep-
ing body and soul together,” in the terms of the day.
We were poor. We didn’t have running water. And
no electricity until the late 1940s.
TI: There is an old saying: “Behind every man is
a strong woman.” How has Donna contributed to
your career?
This is an electronic reprint of the original article
published by the Institute of Mathematical Statistics in
Statistical Science, 2012, Vol. 27, No. 1, 144–159. This
reprint differs from the original in pagination and
typographic detail.
Berry: She contributes to my career by contribut-
ing to me. She gives me a reality check. I say to
her things like, “I don’t think I’m as smart as I once
was.” And she’ll reply, “You used to exaggerate your
intelligence back then, too!” (That’s a joke: Donna’s
too nice to say such a thing, even if true.) She’s
a mate in the truest and warmest senses of the term.
The highlight of my day is dinner, simple, and I stand
at the counter, she sits on the other side, and we
chat about things. She asks how my day has gone
and is interested in the details of who is doing what
to whom, but she’s not too interested in the pro-
fessional aspects of my career. That’s very positive
because we talk about other things. She’s a very
strong person behind me, in the sense of your ques-
tion, but she’s interested in my career only to the
extent that it is part of me.
TI: Your sons, Tim and Scott, have master’s and
Ph.D. degrees in statistics, respectively. How much
were their education and career choices influenced
by growing up with a father as committed to the
field as you are?
Berry: There are a number of statisticians whose
parents are statisticians. Partly it’s because they
have been made aware of statistics as a vocation,
and one that is intellectually satisfying. In the cases
of Tim and Scott, it was sports and the connec-
tion between statistics and sports. I wrote a paper
with Tim before he got his master’s degree that we
published in the American Statistician (Berry and
Berry, 1985). It was on the probability of making
a field goal in American football depending on dis-
tance from the goal and the individual’s record. We
built a geometric model that enabled ranking indi-
vidual kickers. The attraction of statistics for Tim
and Scott was mostly sports, and I provided some
intellectual foundation on the mathematical side.
DS: Now we are going to switch to your education.
Tell us about your undergrad days?
Berry: They weren’t pretty, at least not the first
half of them. My first exposure to amazing intellects
was sobering, especially John Kemeny. I had scored
well on math exams, despite coming from a small
public high school with run-of-the-mill teachers and
no calculus courses. So Dartmouth assigned their
math guru to be my advisor. I remember a recep-
tion at his home for his half dozen advisees. Ke-
meny headed the math department. He was from
Princeton where he had been Einstein’s mathemati-
cian. I was in awe of his abilities and of the abili-
ties of others, students as well as faculty. Kemeny
pioneered computer time-sharing in the 1960s and
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1970s and transformed Dartmouth into the coun-
try’s first computer-intensive campus, becoming its
President from 1970 to 1981. He was co-inventor
(with Thomas E. Kurtz) of BASIC, which became
more widely used in the world than all other lan-
guages combined. Kemeny’s predictions about the
future of computing are amazingly prescient; it’s as
though he had a crystal ball: http://www.youtube.
com/watch?v=HHi3VFOL-AI. Outside of academic
circles Kemeny was best known for leading the 1979
President’s Commission on the Accident at Three
Mile Island. He was from Hungary. When he arrived
in New York City as a 14-year-old, his English was
poor. He told me the following story. There were Re-
gents’ Exams in New York, and they included two
days of English. On the first day he figured out the
scheme of the answers, and so on the second day he
got a perfect score. From then on, his teacher would
never ask him a question unless no one else knew
the answer. If he didn’t know the answer (which he
never did!), she forgave the rest of the class. Kemeny
was brilliant. I knew I would never be as smart or
as accomplished as he was.
In the first and also in the second part of my un-
dergraduate life, the Dean of the College Thaddeus
Seymour was very influential and encouraging. I left
Dartmouth in my second year because I flunked out.
I went into the Army, at Dean Seymour’s suggestion.
Before I left he said, “You’ve got to come back; it
would be a crime against humanity if you don’t come
back.” I’ve thought of that phrase many times since,
and each time it gives me a boost. I was stationed
in Panama with the Army. To gain readmission to
Dartmouth I had to fly back to interview with some
high-level faculty committee headed by Dean Sey-
mour. I was able to convince them I had grown up,
and I had. The Army will do that!
Tom Kurtz had probably the biggest influence on
my becoming a statistician. I knew him as a dupli-
cate bridge player in my first undergraduate stint
and as a teacher in my second. After I had gained
a bit of knowledge about statistics he hired me to
write statistics programs (cumulative distributions,
test statistics, regression analyses, ANOVA, factori-
als, Latin squares, etc.) that became software dis-
tributed with BASIC. This was 1964–1965. I hadn’t
thought about this before, but it may well have been
the first statistics package. Of course, it was crude
by today’s standards. It had a “manual” of sorts:
a series of “REM” statements in the programs. But
at least they contained examples of input and out-
put, which are usually helpful.
Fig. 2. In the U.S. Army in the Panama Canal Zone, 1961,
making intelligence maps.
LI: During your graduate school years at Yale you
were co-advised by Leonard Jimmie Savage (your
primary advisor) and Joseph (Jay) Kadane. What
did you learn uniquely from each of them?
Berry: Recently I have been rereading Savage. He
continues to be the most important influence in my
intellectual being. The atmosphere around him ting-
led with intelligence. He knew as much about every-
thing as anybody could possibly imagine. He could
put his finger on the nub of a problem, and solve it.
He was regarded by some people in the profession
as abrupt and sometimes arrogant and insulting, but
to me he was amazing and wonderful. (Shortly after
Savage died in 1971 I was chatting with a world-
famous statistician. He dissed Savage. I protested,
saying that after all he was human. The reply was,
“He had some human characteristics.” I added, “. . .
and the rest were superhuman.”) We would go into
his office after departmental seminars and we would
discuss what we had learned. Imagine if you can,
having Jimmie Savage as a guide while reading indi-
vidual sentences from Kolmogorov’s Foundations of
the Theory of Probability (Kolmogorov, 1956). Imag-
ine translating Gnedenko from the original for him
to prove that I could read Russian as my second
foreign language requirement, but mainly because
he wanted to know whether the published trans-
lation accurately conveyed Gnedenko’s attitude to-
ward subjective probability (as near as I could tell, it
did). Imagine having him commenting on and react-
ing to every word of your dissertation. It was better
than winning any lottery. Whether in my disserta-
tion or more generally, when I would say something
that didn’t make sense, he wouldn’t tell me it was
wrong. Rather, he would say, “Let’s look at it this
way,” and he would carefully guide me over a cliff,
and while falling I would discover where and why
I had erred.
Seminars at Yale back then were different from
today’s standard fare. They would last at least an
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Fig. 3. Don and Scott playing chess (1975).
hour and a half and sometimes two hours. We would
flesh out the issues, oftentimes leaving the presenter
in the dust. Savage couldn’t see well. If a presenter
had written something on the board that Savage
wanted to ask about he would go up and point to
the spot, peering intently through his Coke bottle
glasses. His questions and comments were inevitably
insightful. They made attending seminars a pleasant
and even pleasurable experience.
Jay Kadane was young at the time, I’m older than
he is, so he had less influence, but indeed he was
a help for me in writing a dissertation, things in
life, and we both have incredible respect for Savage.
DS: What was your first encounter with Bayesian
statistics?
Berry: Tom Kurtz had introduced me to statis-
tics, late in my undergraduate career. He asked me
what I was going to do with my life. I said I didn’t
know, but said I liked probability. He suggested I go
to graduate school in statistics. I asked what it was!
I took a statistics course. I found out later that two
famous statisticians, Tom Louis and Kinley Larntz,
were in the same class. Both later became my col-
leagues and are good friends. But we didn’t do any-
thing Bayesian. Kurtz knew Frank Anscombe when
both were at Princeton and so he suggested that I
apply to Yale.
My first Bayesian encounter was shortly after I got
to Yale. There was a get-acquainted picnic in one of
the early fall weekends. Donna was pregnant with
Scott. When chatting with Anscombe I told him
we had three children, all boys, and that Donna’s
obstetrician said we were due for a girl. I said I
know that’s not right, but the maximum likelihood
estimate—which was the limit of my knowledge—of
the probability of a boy is also clearly wrong. I asked
him how to calculate this probability. He took me
through Laplace’s rule. If you start with a uniform
probability density, he said, the posterior probabil-
ity of a boy is 4/5. He indicated this was on the
high side because the prior distribution is not uni-
form, not as extreme as the MLE, but in the right
direction. His conclusion made sense to me but I had
no idea what he was saying about the mathemat-
ics. Later I asked Savage about it. Did I say Savage
knew everything? He took a book from his shelf by
Corrado Gini of Gini coefficient fame. The book in-
cluded amazing compilations of data on the distri-
bution of gender by sizes of families up to something
like 16 children. He said we could use these data to
figure out a reasonable prior distribution. I decon-
volved what I assumed were beta-binomials to find
the betas. The striking thing was that beta priors
didn’t provide a good fit. Indeed, the samples were
consistent with mixtures of binomials, having big-
ger tails than binomials. But, for example, among
families of size 10 there were more families with 10
girls than with 9 girls. There seemed to be a small
but important point-mass at 0. I found out later
that some women can’t carry a male fetus. Anyway,
I calculated the posterior probability that our un-
born child would be a boy at about 56%.
DS: Now we are going to switch from people who
influenced you, to those that you’ve influenced
through your work.
LI: From your earliest work, “Bandit Problems”
(with Bert Fristedt, dated 1985), your professional
commitment has been to Bayesian methods and de-
cision analysis. Could you tell us how that book was
born and how that work has evolved through your
subsequent work on health-related diagnostics and
clinical trial designs?
Berry: Do you have a month? My thesis was on
bandit problems. One result, probably the most note-
worthy result, was the optimality of the stay-with-
a-winner rule: If an optimal arm is successful, then
it continues to be optimal. It had been shown in
one very special case of dependent arms. I showed
it in the generality of independent arms. (It’s not
true in general for dependent arms.) As I indicated,
I worked closely with Savage on my dissertation.
I submitted a draft of 10 pages. He said it was
great. Ten pages is short, he said, but that’s okay.
I thought I was done. However, he said, we should
try to do a bit more. He took me through five itera-
tions, each time adding some things to be addressed
and in the end we had 60 pages. After that I re-
moved two of the nine chapters that dealt with spe-
cial cases and submitted the rest to The Annals of
Mathematical Statistics (Berry, 1972), precursor of
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The Annals of Probability and The Annals of Statis-
tics. Tom Ferguson was the Associate Editor. He
accepted it without modification, no doubt due to
Savage’s fine-tooth comb. It was a long journal ar-
ticle, at 27 pages. I was lucky and the next paper
I submitted was accepted as well. By the time I got
a paper rejected, 10 papers or so hence, I had built
up the confidence to think that the rejection was
a fluke. Whether true or not, I had come to believe
that important people were interested in what I had
to say. I’ve since seen the opposite happen to young
researchers. Getting one’s first paper rejected can
be so negative that one’s career can take a differ-
ent path. It’s likely that had my early papers been
rejected I wouldn’t have stayed in academia.
I’ve always been attracted by notions of strategy,
games and decision making, including questions of
optimality. My dissertation and early work were ex-
amples. I chose my dissertation subject and brought
it to Savage. I didn’t know much about the litera-
ture in the area and lucked out because little had
been done. On the other hand, the reason little had
been done is that the problem is a bear. Savage
too was interested in strategic questions, as even
a casual reading of How to Gamble If You Must
will reveal. Fristedt, a mathematician who had not
worked in this area, too was interested in strat-
egy. Ed Thorpe had written a book called Beat the
Dealer (Thorp, 1966) on strategies for playing black-
jack. David Heath (who is a mathematician and an-
other collaborator of mine) and Fristedt worked on
improved blackjack strategies. They used them in
Las Vegas and won . . . applied mathematics! Thorpe
called the Heath/Fristedt strategy the best one avail-
able.
I told Fristedt about some of the problems on
which I worked. We attacked a variety of optimiza-
tion issues related to those problems. We did some
things in the book which in retrospect would have
been better off in a journal first. Readers don’t look
for innovations in books. One result in the book is
based on something called the Gittins index. John
Gittins had considered k independent arms with ge-
ometric discounting. That means the current ob-
servation is worth 1, the next is worth alpha, the
next is worth alpha squared, etc. He showed that
this k-armed bandit problem can be reduced to k
two-armed bandit problems where within each you
compare an arm with a known arm and ask which
known arm would make you indifferent between the
arm in question and the known arm. The “equiv-
alent” known arm is the Gittins index and Gittins
showed that the optimal strategy is to always choose
the arm with the biggest Gittins index. Fristedt and
I showed that a Gittins index exists only with geo-
metric discounting. So if you want to maximize the
expected number of successes in five observations,
say, there is no Gittins index result. We should have
put it in a paper first and then the book. The book
had other similar such contributions.
One of the contributions of the book was an anno-
tated bibliography. We reported on all known bandit
papers and what they had contributed to the liter-
ature, if anything! One such paper was published in
Biometrika 1933 by W. R. Thompson (Thompson,
1933). Quite an amazing paper in retrospect. The
focus was calculating the (Bayesian) probability P
that arm 1 is better than arm 2 in two-armed clini-
cal trials and related types of experiments. He said
one should assign the next patient to arm 1 with
probability P (or some function of P ). Actually, he
didn’t quite say “with that probability.” This was
1933. The randomized clinical trial attributed to A.
Bradford Hill in the late 1940s was still to come.
Rather, Thompson said to “fix the fraction of such
individuals to be [assigned to arm 1], until more ev-
idence may be utilized.” Then, “even though [this
strategy is] not the best possible, it seems appar-
ent that a considerable saving of individuals other-
wise sacrificed to the inferior treatment might be
effected.” I leave to you to decide the meaning of
“fraction” and whether Thompson should receive
some credit for the randomized clinical trial, and
in a blocked design no less. (Perhaps randomization
was “in the air” in 1933, especially in the air around
R. A. Fisher.) And Thompson’s adaptive design is
arguably better than Hill’s balanced design that has
so dominated clinical research over the last 60 years.
The reason I tell you about Thompson is that
when I went to M. D. Anderson in 1999 my prin-
cipal goal was to use adaptive designs in phase II
cancer trials. But I wanted to add some random-
ization to otherwise deterministic bandit strategies.
Solving bandit problems requires dynamic program-
ming and the resulting strategies are less than trans-
parent. Moreover, the traditional bandit approach
leads to deterministic strategies. So I opted for the
Thompson procedure, modifying it and applying it
with more complicated endpoints. It is easy to use
and—as opposed to 1933—we can now easily calcu-
late operating characteristics such as Type I error
rate and statistical power, which have become stan-
dard measures for comparing designs. Indeed, we
are using a generalization of the concept in I-SPY2,
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which is a high- profile adaptive phase II drug screen-
ing trial that aims to pair drugs with biomarker sig-
natures in breast cancer (http://www.ispy2.org/).
In a very short time adaptive randomization has
become a big hit in cancer clinical trials. It’s also
a big hit in non-cancer drug trials for assessing the
drug’s dose-response relationship. But with a twist.
In the latter the goal of the treatment assignment—
that is, the dose—is to get information about the im-
portant aspects of the dose-response curve, such as
the minimally effective dose and the maximal utility
dose. In the late 1990s Peter Mueller and I built a de-
sign for Pfizer that was used in a stroke trial called
ASTIN (Berry et al., 2002a). There were 16 doses
including placebo. The design worked perfectly, ex-
ploring the dose-response curve in an efficient fash-
ion, adaptively with some randomization. And the al-
gorithm we built stopped as soon as it was allowed to
do so—proclaiming the drug a dud. More recently,
Scott Berry and I built a design for Eli Lilly that is
being used in a diabetes trial called GBCF. Also
Bayesian, but several improvements over ASTIN.
One is that it was designed to seamlessly morph
into a phase III trial upon sufficiently identifying two
doses to carry forward along with controls. Another
is that it is being driven by a utility function defined
on the various important efficacy and safety charac-
teristics of the drug. Another is that it incorporates
longitudinal modeling with highly informative prior
distributions for the various endpoints.
I continue to work on the theory as well as the ap-
plication of bandit problems. For example, Yi Cheng
is helping Bert Fristedt and me with an updated ver-
sion of our book.
LI: What do you envision for the second edition?
Berry:We’ll do more applications. There have not
been many theoretical advances in the 25 years since
the book came out. There have been essentially none
in discrete-time problems; we have to update more
for continuous time.
LI: Since Bandit Problems (Berry and Fristedt,
1985) you have researched and written prolifically on
topics ranging from introductory to advanced and
from applied to theoretical. Which ones do you re-
gard as most influential and why? Which were most
controversial and why?
Berry: Influence and controversy go hand in hand.
If you’re saying the same thing everybody else is
saying, no one listens. Also, theoretical contribu-
tions don’t create much controversy. If you show
that there is a consequence from a set of assump-
tions, then the extent of applause depends on whe-
ther the argument is correct, whether it is “elegant,”
and how difficult it was to prove. But if you want
to actually use the result, then people will attack
your assumptions. Bandit problems are good exam-
ples. An explicit assumption is the goal to treat pa-
tients effectively, in the trial as well as out. That
is controversial for reasons associated with statisti-
cal philosophy and the inability of the frequentist
approach to have this goal be made explicit. In par-
ticular, it is counter to the 1979 Belmont Report
which clearly states that clinical trials are designed
to test hypotheses and not to treat trial participants
effectively. (Obviously, I disagree and I have demon-
strated that we can do the latter without sacrificing
the former.)
Across the theory/application divide, I’ve written
about the likelihood principle and obviously that’s
controversial. In the early days of the 70s and 80s
I tried to persuade people of its appropriateness but
to no avail.
TI: Michael Krams says you are like Nelson Man-
dela: you were imprisoned, no one listened.
Berry: The analogy is a major stretch, but the
conclusion is correct. About 20 years ago someone
from the FDA approached me on the Metro in DC.
He said he’d heard me talk on many occasions, and
whenever he did, he became a Bayesian . . . for ten
minutes! He said I needed to work on a sustained
release version. The elegance of modern computa-
tional methods helped to provide the necessary sus-
tenance. The ability to actually do what we said we
could do got people to listen, to take Bayesians more
seriously.
Part of the reason statisticians take the older me
more seriously is that I’ve changed over time—as
have they. I’ve become more ecumenical and ar-
guably more politic. And I’ve come to appreciate
even more than I had before what frequentist statis-
tics and frequentist statisticians have achieved over
the years. I used to think it inevitable that the Baye-
sian view would lead to the right answer. That was
na¨ıve. I no longer think Bayesians have an inside
track. Multiple comparisons is an example. No sta-
tistical philosophy has the right answer—and I don’t
think a “right answer” is possible if the requirement
is “one size fits all.” In particular, having inferences
depend on the number of tests can’t be right . . .
and in some forms it is counter to the likelihood
principle. But if you were to give 100 Bayesians and
100 frequentists a quiz, with say 20 settings involv-
ing a range of multiplicity issues, my answers would
probably line up closer to those of frequentists.
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Fig. 4. Testifying before the U.S. Senate (2003).
DS: How have you addressed statistical controver-
sies outside of statistics?
Berry: One of my papers that turned out to be
more controversial than I anticipated was entitled
“Bayesian Clinical Trials.” It appeared in 2006 Na-
ture Reviews Drug Discovery (Berry, 2006). It has
been influential because it was aimed at and was ac-
cessible by nonstatisticians. MDs read it and said to
their collaborating statisticians, “Can we do that?”
Also, in the cancer world we published a paper in
Clinical Trials (Biswas et al., 2009) chronicling the
clinical trials in my first five years at M.D. Ander-
son, focusing on the 200 of them that were Bayesian.
Mithat Gonen wrote the editorial. He said this is
great, but why are such trials confined to one Zip
code? Bayesian clinical trials are not controversial
at my institution. And in cancer research we are re-
garded with a bit of awe because of our ability to
run these trials. But our work is still nascent, and
the world hasn’t embraced our approach with open
arms. But its ears are open. In a way we are an ex-
periment and people want to see how it comes out
before they jump. Across the spectrum of medicine
more people seem to be rooting for us than against
us.
If you read Bayesian polemics from the 1970s and
1980s—including my own—it’s usually arrogant and
even insulting. Some of the terms were excessively
pointed. For example, Bayesians identified which fre-
quentist methods were “incoherent,” or more accura-
tely, lamented that none seemed to be coherent. On
the other hand, Bayesians were accused of being “bi-
ased.” The rhetoric was not all that different from
that of the Fisher/Pearson duels. But we Bayesians
have stopped saying derogatory things, partly be-
cause we have changed and partly because frequen-
tists have been listening. When you’re walking besi-
Fig. 5. Don in his office (2006).
de someone you tend to be cordial; when you’re try-
ing to catch up to tell them something and they
are ignoring what you say, you sometimes yell. One
circumstance of great importance that contributed
to this change in attitude was the work of Telba
and Greg Campbell in the Center for Devices at the
FDA, including their recently published Bayesian
Guidance for Industry (www.fda.gov/downloads/
MedicalDevices/DeviceRegulationandGuidance/
GuidanceDocuments/ucm071121.pdf ). Even if it
did nothing but exist it would lend credibility to the
Bayesian approach. It announces, “Listen to this,
and evaluate it on its merits.”
The most controversial of my work, engendering
death threats, if you can imagine, is not much re-
flected in my publications. In 1997 I co-chaired an
NIH Consensus Development Conference Panel on
mammographic screening for women in their 40s.
I had never published my ideas regarding screening,
but I had a very different attitude from the widely
accepted medical view that finding cancer as early
as possible is uniformly wonderful. I’m not against
screening mammography, as many of my critics have
claimed, but I want to see the evidence for bene-
fits and harms evaluated and presented to women.
It’s such an important issue and it affects so many
people that we must get it right. And if 30 mil-
lion women a year are getting mammograms in the
U.S., we need to know what to tell them about the
benefits and harms. After the Conference I reported
the panel’s conclusions to the National Cancer Ad-
visory Board. Our report created quite a political
storm, including a 98-0 U.S. Senate vote saying that
we were wrong. Interestingly, our recommendations
were almost word for word what the 2009 U.S. Pre-
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Fig. 6. Don in 2006 on the podium with Susan Love, author
of Dr. Susan Love’s Breast Book.
ventive Services Task Force said about screening
mammography for women in their 40s.
As a side note on the Bayesian issue, in 1998 I pub-
lished in the Journal of the National Cancer Insti-
tute (Berry, 1998) a Bayesian meta-analysis of the
eight screening trials. Estimates of individual trial
effects were shrunk in the usual way. I recently com-
pared the updated data from these trials with my
earlier estimates. It’s revealing how similar they are,
and my estimates are much closer than the earlier
MLEs. It’s empirical validation of the appropriate-
ness of Bayesian shrinking.
In 2000 a paper published by the Cochrane Colla-
boration regenerated interest in the question of mam-
mographic screening (Gøtzsche and Olsen, 2000).
There was a U.S. Senate hearing, and they invited
me to present my views, which I did.
LI: How did you get involved in the Senate hear-
ing1?
Berry: When one has views at odds with those
of the establishment, there are two possible conse-
quences. One is that you get ignored as a lunatic.
The other is that you get widely quoted. The lat-
ter happened to me (although most of the estab-
lishment said I was a lunatic, and worse). I haven’t
counted and I know I’ve not seen them all, but I have
been quoted in over 100 newspaper articles concern-
ing screening, including in The New York Times,
The Chicago Tribune, The Los Angeles Times, The
Washington Post, The Wall Street Journal. The rea-
son is not just that my views were anti-establishment.
They rang true to clear-thinking reporters such as
1Transcripted U.S. Senate Hearings on Feb 28, 2002
http://bulk.resource.org/gpo.gov/hearings/107s/78085.
txt.
Gina Kolata (2009a, 2009b) Judy Peres, John Crewd-
son and many others. I was a voice for views they
thought should be presented to women and evalu-
ated for their possible merit. And of course I am
not alone in my views, as the recent United States
Preventive Services Task Force (USPSTF) recom-
mendations make clear.
My name came to be associated with throwing
cold water on the unquestioning lockstep acceptance
of screening. For example, breast cancer incidence
dropped substantially starting in 2002. This coin-
cided with the publication by the Women’s Health
Initiative which showed that postmenopausal hor-
mone therapy is detrimental to the cardiovascular
system as well as increasing the incidence of breast
cancer. Women stopped taking it and breast cancer
incidence dropped. We published a paper in the New
England Journal of Medicine (Ravdin et al., 2007)
implicating hormone therapy. The only serious com-
petitor was the decreased use of mammography over
the same period. One of the co-authors of our pa-
per, Kathy Cronin, who is a terrific statistician at
the NCI, called the decreased use of mammography
the “Berry effect.”
Exactly why the Senate invited me to present my
views at the hearing I do not know. Everybody knew
the Senators were going to come out strongly in fa-
vor of screening because it was the only politically
viable conclusion. Perhaps they wanted token op-
position or perhaps they wanted to be able to say
they’d heard from all sides. Fran Visco, who heads
the National Breast Cancer Coalition, was the only
other presenter on my side of the debate. I loved
her comment to Senator Bill Frist of Tennessee, the
then Senate Majority Leader. In his 5 minutes of
questions for me he harped on the fact that I was
not an MD and he was. Fran deviated from her pre-
pared remarks at the start of her testimony to say
to Senator Frist, “Biostatisticians are the experts in
this debate.”
LI: The most recent mammography recommenda-
tion was released at the end of 2009. In an inter-
view you said: “Consistent with the attitude in U.S.
medicine that if some is good then more is better,
we’ve opted hell-bent for more—with no evidence
[. . .] The standard in Europe is biennial screening.
In the United States we tend to go overboard when
it comes to medicine, and screening is an exam-
ple. We’ve been overselling screening. Sanity has set
in and we’re realizing that we were flying without
wings. Sometimes less is more.” Is this a sign of
progress from earlier debates? Is this going to sur-
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Fig. 7. Panel discussion at the 2009 Bayesian Biostatistics Conference. From left to right: Telba Irony (FDA), Don Rubin
(Harvard), Greg Campbell (FDA), Larry Gould (Merck), Don Berry (M. D. Anderson).
vive the strong reactions against the recommenda-
tions?
Berry: As usual, the best guide to the future is
the past. So I’m not optimistic. The attitudes of
people are very complicated. And sophistication in
evidentiary matters is not necessarily predictive of
rational judgment. Religion is probably the clear-
est example. I know famous statisticians who have
had prostate cancers detected by PSA screening.
They’ve had surgery and suffered the side effects of
incontinence and impotence. They say PSA testing
saved their lives. Any open-minded examination of
the evidence points to the contrary. And it suggests
that PSA testing has robbed them of quality of life.
Will I tell them that? Not any more than I will ar-
gue with a religious fanatic that his is no more likely
to be the true religion than someone else’s.
But let me tell you what really concerns me about
this issue, and what I’m willing to stand up for and
fight against. I once gave a talk at a Gordon Con-
ference dealing with cancer prevention. The princi-
pal presentations before mine were biologists trying
to find cancer ever earlier. For example, they were
working on blood tests to find breast cancer or in-
creased susceptibility to breast cancer. When I got
to speak I asked what they planned to do when they
found breast cancer without knowing where in the
breast it was, or which breast contained it. Dou-
ble mastectomies for millions of women? And for
girls as well? Moreover, they would have no idea
whether the cancer was something that the body
could take care of by itself. Or the cancer might
grow so slowly that it wouldn’t become evident un-
til the women were 100 years old. I told them they
didn’t know what they were doing. To demonstrate
the utility of their findings would require random-
ization, and following women for many years. This
would be an almost impossible hurdle. So that was
my initial part of the presentation. It was like I was
Fig. 8. Don in 2011 in his office with Siddhartha Mukher-
jee, Pulitzer Prize winning author of The Emperor of All Mal-
adies: A Biography of Cancer.
telling religious fanatics that there is no God. Had
there been tomatoes in the room they would have
thrown them. A friend of mine, Bernard Levin, who
at the time was Vice President of Cancer Preven-
tion at M. D. Anderson, relayed one person’s reac-
tion. She consoled him saying, “I feel sorry for you,
Bernard, that you have to be in the same institution
as Don Berry.”
The value of early detection is so ingrained in
people that it’s difficult to get them to think ra-
tionally on the subject. Here’s a helpful calculation.
It takes about 27 doublings to have a breast cancer
big enough to be found on a mammogram. After an-
other couple of doublings it will become symptoma-
tic. (Actually, many cancers become symptomatic
even before they can be detected by a mammogram,
but let’s set that aside.) If it has become metastatic
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Fig. 9. Don with his family.
in the first 27 cycles, it doesn’t matter if you find
it because metastatic disease is fatal. If it becomes
metastatic after 29 or more cycles, then again it
doesn’t matter how you find it. So screening is only
effective if metastasis occurs in a short period of
a cancer’s existence. (And if we get to the point that
we can cure metastatic disease, then it doesn’t mat-
ter when it’s found.) Back to the point of very early
detection. If we find cancer when it’s only 1,000 or so
cells, then we have no idea if we should have found
it. Maybe it’s already metastatic, and finding it is
no help. Or maybe it will never become metastatic,
and finding it does only harm.
The 2009 United States Preventive Services Task
Force has lots of very brave people given what they
concluded. They were widely criticized for it, includ-
ing by a noted radiologist in The Washington Post
(Stein, 2009) for being “idiots.” They walked into
a storm that they hadn’t anticipated would be as
rough as it turned out.
LI: In a related vein, and quoting from http://
cisnet.cancer.gov/, “The Cancer Intervention
and Surveillance Modeling Network (CISNET) is
a consortium of NCI-sponsored investigators that
use statistical modeling to improve our understand-
ing of cancer control interventions in prevention,
screening and treatment and their effects on popula-
tion trends in incidence and mortality. These mod-
els can be used to guide public health research and
priorities.” As regards modeling breast cancer, you
were the lead author of a paper published in the New
England Journal of Medicine (Berry et al., 2005):
“Effect of Screening and Adjuvant Therapy on Mor-
tality from Breast Cancer.” Could you tell us a lit-
tle about your work with the CISNET consortium?
What were the unique contributions CISNET
brought to the debate on screening mammography?
Berry: There has been substantial progress in re-
ducing mortality to breast cancer in the U.S. (about
24% between 1990 and 2000) and more generally.
What interventions were responsible? Was it screen-
ing mammography? Was it adjuvant therapy, ta-
moxifen and polychemotherapy? The paper that you
mention reports on the efforts of seven modeling
groups in addressing these questions. I think this
paper was unique in reporting and comparing the
efforts of multiple modeling groups in addressing
the same questions and using the same data. The
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Fig. 10. Don and Donna.
M. D. Anderson model (Berry et al., 2006) was one
of the seven. It was the only model that took a Baye-
sian perspective. We got quantitatively different an-
swers, but, well, in the words of a New York Times
editorial: “What seems most important is that each
team found at least some benefit frommammograms.
The likelihood that they are beneficial seems a lot
more solid today than it did four years ago, although
the size of the benefit remains in dispute” (NYT
Editorial, 2005). One of my favorite headlines was
CNN’s: “Statistical Blitz Helps Pin Down Mammog-
raphy Benefits” (Peck, 2005).
More recently, we Breast CISNETers were asked
by the aforementioned 2009 USPSTF to model sev-
eral matters related to screening mammography. Of
course we accepted. And we were pleased that they
used our results in their recommendations. Our pa-
per (lead author, Jeanne Mandelblatt) was published
as a companion article to their recommendations in
the Annals of Internal Medicine (Mandelblatt et al.,
2009). One set of issues the TF asked us to address
was the relative benefits and risks of biennial ver-
sus annual screening for women aged 50 to 74. This
important question was never addressed in the ran-
domized screening trials. And comparing across tri-
als doesn’t suggest increased benefit for more inten-
sive screening. Our modeling concluded that there
is little benefit and substantially greater risks as-
sociated with doubling the frequency of screening.
The TF recommended biennial screening, modify-
Fig. 11. Don, where he does his best thinking.
ing their earlier recommendation of annual screen-
ing.
The most controversial TF recommendation was
“against routine screening mammography in women
aged 40 to 49 years.” Our CISNET models had ad-
dressed this question. Our conclusions were consis-
tent with the benefits seen in the randomized screen-
ing trials. We concluded that “Initiating biennial
screening at age 40 years (vs. 50 years) reduced
mortality by an additional 3% (range, 1% to 6%),
consumed more resources, and yielded more false-
positive results.”
A unique contribution of CISNET to the effective-
ness of screening mammography was the role of ad-
juvant therapy. Most of the randomized trials were
conducted in the era before the use of such therapy.
Their relevance for today is questionable. Perhaps
therapy makes up for any benefit seen with screen-
ing in the pre-adjuvant therapy era and so screening
is now irrelevant. Or maybe being able to treat pa-
tients with anti-cancer drugs enhances the effective-
ness of screening. In our models we found that the
mortality benefits of screening and adjuvant therapy
were essentially independent, and therefore additive.
LI: So what should statisticians be doing to help
understand what evidence or lack of evidence there
is regarding mammography?
Berry: Randomizing women to get screened ver-
sus not screened is now impossible. So modeling is
the only recourse. And in the modeling process it
is critical to assess uncertainty in the conclusions.
I might add that the Bayesian approach is ideal for
such assessment because it treats the model param-
eters as random variables.
LI: Mutations to BRCA1 and BRCA2 have been
linked to breast and ovarian cancers. You have been
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quoted to say that “there is no BRCA3” meaning
that no gene of the importance of the BRCA1 and 2
was going to be found in breast cancer. It seems that
you have been right on! Lesser players have come up,
but they have been shown to be minor. Can you tell
us how you come up with such a prediction in those
early days that proved to be so accurate? How did
your clinical colleagues react then and now to that
prediction?
Berry: In the 1990s, Duke had a SPORE in breast
cancer. (SPOREs are Specialized Programs of Re-
search Excellence. These are megagrants from the
National Cancer Institute to teams of researchers
working to translate basic science into clinical prac-
tice.) I was the PI of the Biostatistics Core of the
SPORE. Giovanni Parmigiani and I had one of the
projects in the SPORE.We planned to build a model
to assess the role of family history in addressing
whether an individual carried a mutation of BRCA1
or BRCA2 (Berry et al., 1997; Parmigiani, Berry
and Aguilar, 1998). My attitude was that this was
just the beginning, something that would lead us to
doing really good things to help the other projects.
And I thought it might provide a tool for the breast
cancer research community. But I regarded it as just
a start. It was to be the easy part. It was not quite so
easy. We did it, mainly due to Giovanni’s ingenuity
and diligence. We married Mendel and Bayes. The
end result was BRCAPRO,2 which is now widely
used by genetics counselors. I don’t know where
it stands in rankings of the contributions by the
SPORE programs of the NCI, but it’s not at the
bottom.
So to your question. Giovanni and I and others
did a validation study of BRCAPRO (Berry et al.,
2002b). We had family histories of about 300 indi-
viduals for whom we also had BRCA1 and BRCA2
mutation status, although we didn’t know all the
possible mutations of these two genes. We assessed
each individual’s BRCAPRO and compared it to
that individual’s mutation status. We found an ex-
cellent fit. The proportion of carriers within narrow
categories of BRCAPRO was about that value of
BRCAPRO, with a slight amount of overestimation.
So there was very little room for another gene. Such
2BRCAPRO is a statistical model, with associated soft-
ware, for assessing the probability that an individual car-
ries a germline deleterious mutation of the BRCA1 and
BRCA2 genes, based on family history of breast and ovarian
cancer. Source: http://astor.som.jhmi.edu/BayesMendel/
brcapro.html.
genes might well exist, but they had to be either
very rare or have very low penetrance (few carri-
ers getting cancer) or both. In any case, trying to
find such a gene is like trying to find a needle in
a haystack. I told some BRCA3 seekers that they
were wasting their time. This was over 10 years ago.
I was pooh-poohed. They kept looking. But as you
say, they’ve never found it.
TI:What do you see as the primary impact of your
research and writings on Bayesian methods and de-
cision analysis for health-related diagnostics (espe-
cially breast cancer) and for clinical trials of drugs
and devices?
How has your work been contributing to the treat-
ment of cancer patients and what do you think were
your major breakthroughs? What do you hope can
be achieved in the future in terms of treatment of
such patients?
Berry: The impact I’ve had in the cancer world
is only partly on the Bayesian side. When I moved
fromMinnesota to Duke in 1990, Steve George asked
me to be the statistician on Breast Cancer Commit-
tee of the Cancer and Leukemia Group B (CALGB).
This is a national oncology group that runs clinical
trials and is funded by the National Cancer Insti-
tute. Getting my ideas accepted was hard. Craig
Henderson chaired the committee. In our early meet-
ings he would set me up and knock me down. He in-
dicated that my ideas were radical and inconsistent
with science. In a profile of me in Science magazine,
Jennifer Couzin (Couzin, 2004) picks up this thread:
“Berry would be the lead statistician for CALGB’s
breast cancer studies. He was not greeted warmly.
‘I objected rather strenuously,’ recalls I. Craig Hen-
derson, a breast oncologist at the University of Cali-
fornia, San Francisco, who had heard that Bayesians
were ‘loosey-goosey’ in adhering to the rules. Hen-
derson subsequently had a change of heart: Last
year, he was the first in a string of authors on one of
the largest breast cancer studies Berry has designed,
with more than 3,000 women. Its factorial design
revealed that adding the drug paclitaxel (Taxol) to
standard chemotherapy is beneficial, and that high
doses of doxorubicin (Adriamycin), one of the most
toxic chemotherapy agents, don’t fight cancer any
more effectively than lower doses. This came as
a great surprise, and some criticized the study for
its unusual methodology.” Craig Henderson became
one of my best friends. We learned from each other
and we drifted toward a common view of medical
research.
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There is a moral to this story for young statisti-
cians. Pay your dues. Learn the lay of the land before
you set out to change it. Build your own credibility
before you try to rebuild anything. Show that you
understand and can deal with the status quo. How-
ever elegant are your ideas, innovations are viewed
with suspicion.
The future of breast cancer treatment? We are
getting better and better at understanding the dis-
ease, biologically and empirically. Regarding the lat-
ter, trials such as I-SPY2 will help us pair patient
characteristics with appropriate therapies, including
with no therapy. This is sometimes called “person-
alized medicine.”
TI: I-SPY and ISPY-23 are incredibly innovative
clinical trials. Could you talk a little about what
they are, their advantages and the challenges of im-
plementing them? How are they seen by patient ad-
vocates, the pharmaceutical and medical device in-
dustry and by regulatory agencies?
Berry: When breast cancer is first diagnosed, the
tumor is usually removed and the patient is given
systemic hormone therapy and/or chemotherapy.
The I-SPY trials are built on a platform of neo-
adjuvant treatment in which the order is reversed.
The tumor is left in the breast and systemic therapy
is delivered, for 6 months or so, before the tumor is
removed. Actually, the tumor may be gone, having
been eliminated by the therapy. That is the endpoint
of the I-SPY trials—the presence or not of tumor at
surgery.
I-SPY2 is adaptive in the sense that we use ac-
cumulating information to guide the treatment of
patients in the trial. But we don’t wait for 6 months
to get information about how well the patient is do-
ing. We use longitudinal modeling of tumor burden
based on breast imaging with MRIs.
I-SPY2 is a phase II drug screening trial. Actually,
it’s more a process than a trial. We’re starting with
five experimental therapies plus control. For the pur-
poses of the design and for assigning treatment we
categorize breast cancer into 8 biomarker subtypes.
Of the 255 combinations of the 8 biomarker subtypes
we’ve identified 10 “biomarker signatures” that make
biological sense and have marketing relevance. We
use adaptive randomization, assigning a patient with
higher probabilities to better performing therapies
for that patient’s subtype. This moves better per-
3The I-SPY project is a national study to identify biomark-
ers predictive of response to breast cancer therapy. [Source:
http://tr.nci.nih.gov/iSpy].
forming therapies through the process more quickly,
as well as providing better therapy to trial partici-
pants.
Traditional clinical trials are discrete entities.
They live like frogs on their private lily pads. Their
precise role in drug development must be better de-
fined. I sometimes ask investigators, “So what will
you do next depending on the results of your trial?”
You’d be surprised at the muddled answers. A result
is that phase III oncology drug trials fail between 60
and 70 percent of the time.
Perhaps it’s just the Bayesian in me, but I think
a trial should have a theme, a long-term outlook,
a strategy. Its design should be viewed as the next
action in a bigger decision problem. Think of a game
of chess. The best chess players make moves in the
middle game while looking forward to the end game.
The entire focus of I-SPY2 is on what comes next:
phase III. For each therapy we continually ask what
population of patients (defined by biomarker signa-
ture)—if any!—would be most appropriate in a small,
focused phase III trial. So we consider 10 different
phase III trials, one for each prospectively defined
signature. The answers evolve over time, until the
therapy is ready to move to phase III or be aban-
doned for futility. Graduation to phase III is based
on current (Bayesian) predictive probabilities of suc-
cess in a small phase III trial, focusing on the ideal
biomarker signatures.
Quite obviously, in view of the various multiplici-
ties, false positives abound. Beating them down re-
quires somewhat larger sample size than is tradi-
tional: a maximum of 120 patients per treatment
arm, although the expected sample size is substan-
tially less. We show by simulations that we control
Type I error rates.
Our approach in I-SPY2 will lead others to de-
sign better, more informative, early phase trials and
greatly reduce the failure rate of phase III trials . . .
and treat patients better in the process. This is al-
ready happening, despite the fact that I-SPY2 has
just started to accrue patients.
The principal investigator of both I-SPY trials is
Laura Esserman of the University of California at
San Francisco. Without her innovative ideas and un-
inhibited approach to clinical research, these trials
would never have existed.
TI: Your current department has been largely in-
fluenced by your views and, in fact, most clinical
trials designed at M.D. Anderson have Bayesian de-
signs. However, Bayesian designs are not widespread
in other (research/university) hospitals. In your view,
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what should be done so that Bayesian designs would
have wider acceptance? What do you see as the cur-
rent major obstacle to the wide use of Bayesian clin-
ical trials?
Berry: Actually, not quite “most,” but close to
half the trials we design are Bayesian. The major
obstacle outside of M. D. Anderson is the lack of
Bayesian statisticians who have built up the credibil-
ity that I mentioned earlier, and who understand the
pitfalls of taking the Bayesian approach in clinical
trials. Graduates of our best “Bayesian schools” may
be great at analysis but some don’t have a clue about
experimental design. And even if they’ve studied ex-
perimental design, they have no understanding of
clinical trials. At M. D. Anderson, when we tell an
investigator that the Bayesian perspective is ideally
suited for his or her trial, there is no pushback.
They accept that we know what we’re doing and
they trust us. That is not a standard reaction else-
where. And, regrettably, I’m happy for that! I tell
you quite candidly that there are very few Bayesians
outside of M. D. Anderson and Berry Consultants
that I would trust to design a clinical trial, including
some who have designed clinical trials! That must
change. It can change only through education and
better, apprenticeships. Unfortunately, such change
is slow.
LI: You have traveled around the world to advo-
cate for Bayesian designs and have even been tagged
“The Bayesian Tsunami.” Could you tell us a little
bit about that story? How do you see the propaga-
tion of the Bayesian ideas around the world?
Berry: The tsunami title comes from the front-
page article of a pharmaceutical newsletter in Japan,
with my photo, and some words that I can’t read.
So I asked my Japanese friends to translate. It says
something about the coming Bayesian tsunami in
clinical trials. But there’s actually not much of a
Bayesian tsunami in Japan. I am going there next
month for a meeting on breast cancer to talk about
innovative designs in cancer. The circumstance is a
bit like Center for Devices and Radiological Health
(CDRH) at the FDA in the late 1990s in that they
started to get serious about science at the same time
that they started getting serious about efficiency in
product development. They are open minded. There
is a famous biostatistician there named Ohashi who
is very interested in Bayesian things, but it’s a stretch
to say they are in the Bayesian camp. They are inter-
ested, but they have little experience. Next month
I’m also going to Brussels and London to give talks
about Bayesian adaptive designs. And we have fre-
quent visitors to M. D. Anderson from around the
world with the goal of learning what we do.
But change is hard. Your native country is an ex-
ample. Scott and I designed an international trial
for a major pharmaceutical company. Bayesian ap-
proach. Adaptive throughout, including morphing
into a confirmatory stage. Happily, most sites around
the world signed on. But not the site in Brazil. They
said they couldn’t accept a design that they didn’t
understand.
TI: You have held tenured positions at Univer-
sity of Minnesota, Duke and M. D. Anderson. You
have worked with numerous government groups and
pharmaceutical companies. Your career has taken
you across institutions spanning academics, govern-
ment, and industry. How important has the ability
to navigate across these boundaries been to the suc-
cess of your career?
Berry: It’s better to be lucky than good. Going
back to the Task Force, I ask people a thought ques-
tion. It’s obvious that politicians don’t understand
science. The U.S. Senate passed a resolution after
the Consensus conference on mammographic screen-
ing in 1997, a strange resolution, seeming to say that
mammography will be effective, as though their law-
making ability extends to amending the laws of na-
ture! (Milton Berle said it: “You can lead a man to
Congress but you cannot make him think!”) This is
the resolution that I mentioned earlier, the one that
passed 98 to 0. The Senate insisted that the NCI
recommend screening to women in their 40s. Sena-
tor Arlen Specter told the director of the NCI that
if they wanted funding for the next year they would
recommend mammography screening for women in
their 40s. Since NCI wanted to be funded they made
the recommendation. The Task Force, on the other
hand, consisted of people who were adept at science,
but who were politically na¨ıve, and who stepped into
a political morass. So here’s the thought question:
Are politicians more ignorant about science than sci-
entists are about politics?
I’m at least as politically na¨ıve as the Task Force.
Regarding the boundaries you mention, I’ve not nav-
igated them at all well. I’ve said things—especially
when I was young and green—that made my subse-
quent challenges even more difficult. Somehow, be-
ing right was enough when I was young, even if no
one paid any heed. But I was lucky, including by
outliving some of my colleagues. And with time I be-
came more pragmatic, more politic. I want to change
the world, but to the extent I’ve been successful, it’s
more luck than planning.
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DS:How do we improve as a profession doing what
you do so naturally, that is, bringing science to the
service of society? You tell us you’ve been able to
do this by luck, but is there anything we can do in
training statisticians to make that luck happen more
often?
Berry: I tell my young faculty to worry about big
questions, those important to society. It can be in
physics, biology, medicine, paleontology (one of my
favorites is “what killed the dinosaurs?”). Study it.
Assess the uncertainties. Critique the available evi-
dence. Tie yourself to some smart people in the sub-
ject matter. Go public. And work hard to state your
conclusions concisely and with as few words as pos-
sible.
When I became appalled at the sorry science be-
hind the anti-doping crusade in sports I wrote a com-
mentary about it that was published in Nature (Ber-
ry, 2008). It created a stir. Clearly I was lucky that
Nature published the piece. I attribute some of this
to my fussiness. I revise and revise. I beat on every
word to see if I can make it give up the ghost. And
I try to use language that resonates. I’m not neces-
sarily good at it, but only hard work has a chance of
paying off. Unless you’re Mozart (remember Salieri’s
marvel in “Amadeus” at the lack of erasures in Mo-
zart’s musical scores, just as if he had taken down
“dictation from God”?) your unadulterated first ver-
sion will be eminently forgettable.
DS:Where do you see Bayesian statistics heading?
Berry: The future is bright. The spirit of ecu-
menism is pervasive in modern statistics circles. In
tomorrow’s ENAR presentation Janet Wittes is go-
ing to talk about the marriage between Bayesians
and frequentists. As I get older I realize that hav-
ing impact means taking small steps. You can’t sell
the whole thing at once. Dalene and I have writ-
ten about a fully Bayesian approach complete with
decision analysis (Berry and Stangl, 1996; Stangl
and Berry, 2000). The statistics world will one day
be ready for it, but it’s not now, at least not on
a broad basis. Instead, at least in biostatistics, we
Bayesians do things that fit into and partially em-
ulate the frequentist paradigm. We achieve some
benefits from the Bayesian perspective, but many
others are still on the horizon. Meanwhile, we have
our foot in the door. As the ideas become accept-
able and more widely understood, it will become
clearer to others whether we are adding something
to the world, including to the frequentist world. For
example, I consider Type I error rates to be essen-
tial in a regulatory setting. I see even more com-
promise in the immediate future, and like Janet
I see marriage. If James Carville and Mary Matalin
can marry, given their very different political per-
spectives, it’s a cakewalk for Bayesians and frequen-
tists.
Another reason the future looks bright. In one of
my examples in tomorrow’s talk, choosing sample
size of a clinical trial, I argue against the notion that
one size fits all. I rail against the consulting statisti-
cian who says, okay, in your two-armed trial you aim
to reduce hazard by 25%, your Type I error rate is
5%, two-sided, 80% power, control median time to
event is 6 months, you want to accrue for 3 years
and follow patients for an additional year, so you
need about 12 patients per month or 432 in total.
Where are the questions about the disease? About
its prevalence? What about the implications of what
will be learned from the trial? The disease may be
a rare pediatric cancer and there may not be 432
patients in the world. Good frequentist statisticians
ask these questions and they learn as much as possi-
ble about the disease. They’ll come up with a doable
design. But they do it in spite of their philosophy
and with little help from it. The fully Bayesian ap-
proach provides a formalism for addressing all such
questions. Pediatric cancer may be the ideal pro-
totype for developing this formalism in clinical re-
search.
DS: Thinking about your professional life, what
have been the most rewarding moments/experiences?
Berry: Teaching. Lurdes. Seeing former students
and colleagues do good things and achieve recogni-
tion. But not just rewards from teaching or mentor-
ing graduate students. In classes, seeing light bulbs
flash on. Listening to my former students and col-
leagues make statements, use arguments, etc., that
I recognize having said myself. It’s such a compli-
ment. I smile . . . and my shirt buttons pop! I’ve
had some success affecting the way people outside
of academia think about things, but it’s really teach-
ing and mentoring that are the most rewarding.
DS: For what would you most like to be remem-
bered?
Berry: That’s a hard question. On the Bayesian
side, I hope 50 years from now, people will look
back and say this guy had something to do with
how we think today. He put some teeth into the
elegant jaws of the Bayesian paradigm. On the bio-
statistical/medical side, I’d like to be thought of as
having improved the lives of thousands of patients
with what were once regarded to be lunatic ideas
about clinical research.
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DS: Are there any other topics you would like to
touch upon?
Berry: I need to get on my bicycle and think. But
since I’m not on my bicycle I can’t think of any.
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